Female fertility preservation for family planning: a position statement of the Italian Society of Fertility and Sterility and Reproductive Medicine (SIFES-MR)
- PMID: 39030346
- PMCID: PMC11405660
- DOI: 10.1007/s10815-024-03197-4
Female fertility preservation for family planning: a position statement of the Italian Society of Fertility and Sterility and Reproductive Medicine (SIFES-MR)
Abstract
Purpose: This position statement by the Italian Society of Fertility and Sterility and Reproductive Medicine (SIFES-MR) aims to establish an optimal framework for fertility preservation outside the standard before oncological therapies. Key topics include the role of fertility units in comprehensive fertility assessment, factors impacting ovarian potential, available preservation methods, and appropriate criteria for offering such interventions.
Methods: The SIFES-MR writing group comprises Italian reproductive physicians, embryologists, and scientists. The consensus emerged after a six-month period of meetings, including extensive literature review, dialogue among authors and input from society members. Final approval was granted by the SIFES-MR governing council.
Results: Fertility counselling transitions from urgent to long-term care, emphasizing family planning. Age, along with ovarian reserve markers, is the primary predictor of female fertility. Various factors, including gynecological conditions, autoimmune disorders, and prior gonadotoxic therapies, may impact ovarian reserve. Oocyte cryopreservation should be the preferred method. Women 30-34 years old and 35-39 years old, without known pathologies impacting the ovarian reserve, should cryopreserve at least 12-13 and 15-20 oocytes to achieve the same chance of a spontaneous live birth they would have if they tried to conceive at the age of cryopreservation (63% and 52%, respectively in the two age groups).
Conclusions: Optimal fertility counselling necessitates a long-term approach, that nurtures an understanding of fertility, facilitates timely evaluation of factors that may affect fertility, and explores fertility preservation choices at opportune intervals.
Keywords: Family planning; Fertility preservation; Oocytes cryopreservation; Ovarian reserve.
© 2024. The Author(s).
Conflict of interest statement
All authors declare to have no conflicts of interest related to the present paper.
Figures


Similar articles
-
The relevance of female overweight in infertility treatment: a position statement of the Italian Society of Fertility and Sterility and Reproductive Medicine (SIFES-MR).J Assist Reprod Genet. 2025 Apr;42(4):1343-1354. doi: 10.1007/s10815-024-03379-0. Epub 2025 Feb 4. J Assist Reprod Genet. 2025. PMID: 39903407 Free PMC article.
-
Oocyte cryopreservation review: outcomes of medical oocyte cryopreservation and planned oocyte cryopreservation.Reprod Biol Endocrinol. 2022 Jan 7;20(1):10. doi: 10.1186/s12958-021-00884-0. Reprod Biol Endocrinol. 2022. PMID: 34996479 Free PMC article. Review.
-
A prospective study of women and girls undergoing fertility preservation due to oncologic and non-oncologic indications in Sweden-Trends in patients' choices and benefit of the chosen methods after long-term follow up.Acta Obstet Gynecol Scand. 2019 May;98(5):604-615. doi: 10.1111/aogs.13559. Epub 2019 Mar 18. Acta Obstet Gynecol Scand. 2019. PMID: 30723910
-
[Fertility preservation techniques in women of reproductive age ].Rev Med Suisse. 2014 Oct 22;10(447):1961-2, 1964-6, 1968. Rev Med Suisse. 2014. PMID: 25518205 French.
-
In vitro maturation of human immature oocytes for fertility preservation.Fertil Steril. 2013 Apr;99(5):1173-81. doi: 10.1016/j.fertnstert.2013.01.141. Epub 2013 Feb 20. Fertil Steril. 2013. PMID: 23433515 Review.
Cited by
-
"Forever fertile": ovarian tissue cryopreservation for an extended reproductive lifespan.J Assist Reprod Genet. 2025 Jun 28. doi: 10.1007/s10815-025-03554-x. Online ahead of print. J Assist Reprod Genet. 2025. PMID: 40581687
-
Fertility preservation in young patients with breast cancer: insights from the Gemme Dormienti network.Ther Adv Med Oncol. 2025 Jul 13;17:17588359251341210. doi: 10.1177/17588359251341210. eCollection 2025. Ther Adv Med Oncol. 2025. PMID: 40661992 Free PMC article.
References
-
- ISTAT. Indicatori demografici, anno 2023. 2023. [Online]. Available: https://www.istat.it/it/files//2023/12/CENSIMENTOEDINAMICADEMOGRAFICA202.... Accessed 20 Jan 2024.
MeSH terms
LinkOut - more resources
Full Text Sources